Vaxcyte Inc (PCVX)
88.54
+0.15
(+0.17%)
USD |
NASDAQ |
Nov 22, 16:00
89.00
+0.46
(+0.52%)
After-Hours: 20:00
Vaxcyte Enterprise Value: 8.855B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 8.855B |
| November 21, 2024 | 8.836B |
| November 20, 2024 | 8.533B |
| November 19, 2024 | 8.673B |
| November 18, 2024 | 8.599B |
| November 15, 2024 | 8.642B |
| November 14, 2024 | 9.371B |
| November 13, 2024 | 9.863B |
| November 12, 2024 | 10.21B |
| November 11, 2024 | 10.74B |
| November 08, 2024 | 11.11B |
| November 07, 2024 | 10.62B |
| November 06, 2024 | 10.79B |
| November 05, 2024 | 11.23B |
| November 04, 2024 | 11.09B |
| November 01, 2024 | 11.19B |
| October 31, 2024 | 11.05B |
| October 30, 2024 | 11.02B |
| October 29, 2024 | 10.95B |
| October 28, 2024 | 11.86B |
| October 25, 2024 | 11.87B |
| October 24, 2024 | 11.80B |
| October 23, 2024 | 11.77B |
| October 22, 2024 | 11.84B |
| October 21, 2024 | 12.18B |
| Date | Value |
|---|---|
| October 18, 2024 | 12.19B |
| October 17, 2024 | 12.20B |
| October 16, 2024 | 12.49B |
| October 15, 2024 | 12.19B |
| October 14, 2024 | 11.89B |
| October 11, 2024 | 12.06B |
| October 10, 2024 | 11.71B |
| October 09, 2024 | 11.74B |
| October 08, 2024 | 11.72B |
| October 07, 2024 | 11.32B |
| October 04, 2024 | 11.67B |
| October 03, 2024 | 11.64B |
| October 02, 2024 | 12.04B |
| October 01, 2024 | 12.20B |
| September 30, 2024 | 12.04B |
| September 27, 2024 | 12.55B |
| September 26, 2024 | 12.34B |
| September 25, 2024 | 12.59B |
| September 24, 2024 | 12.86B |
| September 23, 2024 | 12.42B |
| September 20, 2024 | 12.80B |
| September 19, 2024 | 13.04B |
| September 18, 2024 | 12.97B |
| September 17, 2024 | 13.00B |
| September 16, 2024 | 12.69B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
524.06M
Minimum
May 10 2021
13.04B
Maximum
Sep 19 2024
2.997B
Average
1.822B
Median
Oct 23 2020
Enterprise Value Benchmarks
| Pfizer Inc | 202.30B |
| Merck & Co Inc | 274.49B |
| Embecta Corp | 2.123B |
| Arrowhead Pharmaceuticals Inc | 1.879B |
| Dyne Therapeutics Inc | 2.298B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -103.12M |
| Total Expenses (Quarterly) | 139.63M |
| EPS Diluted (Quarterly) | -0.83 |
| Earnings Yield | -5.20% |